Bull of the Day: Globus Medical (GMED)

Why It Matters

The upgraded earnings outlook highlights structural profit growth, positioning Globus as a rare high‑margin med‑device play. Investors see a compelling long‑term opportunity as the spine business outpaces market growth and recurring revenue from enabling technologies expands.

Key Takeaways

• Q1 EPS $1.12 beat $0.92 estimate, revenue up 27%
• Full-year EPS guidance lifted to $4.70‑$4.80, revenue flat
• Analyst EPS forecasts rose 20% for this year, 23% next
• Spine franchise growing ~10% quarterly, beating 3% market growth
• Q1 gross margin 69.2%, aiming for mid‑70s long term

Pulse Analysis

Globus Medical has emerged as a standout performer in the crowded musculoskeletal‑device market, posting the most aggressive earnings‑revision streak among its peers. The company’s Q1 results not only shattered consensus expectations but also triggered a wave of analyst upgrades, pushing the consensus EPS forecast for the current year up by 20 percent. In a sector where growth is often incremental, Globus’s ability to lift guidance while keeping revenue targets steady signals a structural improvement in profitability rather than a one‑off boost.

The financial snapshot underscores why investors are taking notice. Adjusted EBITDA climbed to $245.3 million, delivering a 32.3 % margin that eclipsed the prior‑year 29.7 % level, while revenue surged 27 % to $759.9 million. More striking is the gross‑margin lift to 69.2 % in Q1, with management targeting the mid‑70s range, a rare achievement for a company of Globus’s scale. The raised non‑GAAP EPS outlook of $4.70‑$4.80, paired with unchanged revenue guidance of $3.18‑$3.22 billion, suggests that margin expansion is becoming the new norm.

Operationally, the spine franchise remains the engine, delivering roughly 10 % quarterly growth and capturing market share far above the 3 % industry rate. Enabling technologies such as the SCRIPPT patient‑specific spacers and the expanding robotics lease model promise recurring revenue streams that could further lift margins. The lingering Nevro spinal‑cord stimulation unit adds short‑term headwinds, but management views it as a timing issue rather than a strategic flaw. Technically, the stock has found support near the $75 level and is poised to retest the 50‑day moving average, making the current price an attractive entry point for long‑term investors.